ALLR

Allarity Therapeutics Inc. (ALLR) | Rumor.io

Allarity Therapeutics

ALLR

Attention (50-day avg)0%

Attention rank (50-day avg)#810

Bullish sentiment (50-day avg)75%

Price to earnings ratio0.12

Market capitalization15.4M

Earnings per share-0.79

Dividend yield (TTM)—

Revenue (annual)320K

Net income (annual)-11.2M

Social

What share of all stock conversation is about ALLR?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% -0.01	0% +0	0% +0	0% -0.02

Sep 15

Allarity Therapeutics, Inc. (ALLR) granted Japanese patent for Stenoparib DRP companion diagnostic, strengthening its development.
The patent establishes an IP moat for ALLR in the multi-billion dollar Asian oncology sector through 2039, materially de-risking ongoing Phase 2 clinical trials.
The development of Stenoparib DRP companion diagnostic has significant potential, according to some market participants.

Generated by AI

Sentiment

Of the messages about ALLR that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100% +12.24	72.29% +52.06	61.93% -28.47	75.2% -11.86
Bearish	0% -12.24	27.71% -52.06	38.07% +28.47	24.8% +11.86

Bullish· May 27

The author believes $ALLR has the potential for a big break out, citing a strong price increase.
The stock is expected to move higher, with a target price of $1.87 and potentially even $2.30.
The author is confident in the stock's ability to make significant gains, comparing it to other successful stocks that have experienced rapid price increases.

Bearish· Feb 3

The company's recent offering of shares may be part of a scam, as it was launched during the FDA shutdown when no news was expected.
The stock's price compression and fading downside momentum suggest a sharp move, which could be downward.
The company's leadership and PR efforts are being criticized, with some calling the CEO a "scam artist" and the stock a "trash" that will inevitably sink.

Generated by AI

Topics

Of the messages about ALLR that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	100%	89.2%	74.02%
Technical Analysis	0%	0%	10.8%	21.86%
Controversies	0%	0%	0%	1.03%
Earnings	0%	0%	0%	0.75%
Macro	0%	0%	0%	0.83%
Analysts	0%	0%	0%	1.5%

Announcements· Sep 22

Allarity Therapeutics, Inc. ($ALLR) presents new Phase 2 clinical data for Stenoparib/2X-121, showing a landmark median overall survival (mOS) exceeding 25 months in platinum-resistant ovarian cancer.
The company has secured a $2.5 million private placement at $1.60 per share, with an institution, in addition to its Fast Track designation and multiple upcoming conferences.
The data presented at the American Association for Cancer Research (AACR) demonstrate clinical benefit in both BRCA-wt and BRCA-mut patients, indicating a potential for Stenoparib to reach a larger patient population.

Technical Analysis· Aug 27

$ALLR has formed a cup and handle pattern, potentially indicating a continuation of the upward trend.
The stock has reached the target of a double bottom pattern on the 15-minute chart and is nearing the target of a falling wedge pattern.
The stock is expected to break out if it opens near $0.50, targeting $0.70 and $0.90, following FDA approval for a cancer treatment.

Generated by AI

Community

Of the messages about ALLR, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	54.29%	76.87%	85.99%	91.71%
Newcomers	45.71%	23.13%	14.01%	8.29%

Regulars· Sep 11

Allarity Therapeutics, Inc. (ALLR) is planning to raise $100M+ through a proposed IPO, with the stage set for stenoparib news to be announced.
The company's SPAC, Allarity Acquisition Corp. (ALLNU), is expected to have a base offering size of $100M, with the sponsor owning approximately 25% of the company.
Stenoparib's patent protection could potentially be extended, and the company could apply the same strategy to other drugs, providing a 25% economic benefit.

Newcomers· Sep 24

Newcomers to Allarity Therapeutics are focusing on the company's clinical trial results, with some highlighting the stock's potential for growth due to its promising oncology treatments.
The recent funding of $250M is seen as a positive development for Allarity Therapeutics, potentially positioning it ahead of competitors in the aerospace and defense sectors.
The stock's recent performance is being attributed to Allarity's focus on expanding its therapeutic pipeline, which could yield positive results and reflect broader market trends.

Generated by AI

- Expanded laboratory capabilities support deeper mechanism-of-action research for stenoparib - New proteomics and cell line capabilities will broaden Allarity’s research capabilities to enable external partnerships TARPON SPRINGS, Fla., September 28, 2026 – Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a differentiated, dual PARP and WNT pathway inhibitor— today announced that

1d agoYahoo Finance Singapore

Allarity Therapeutics Granted Japanese Patent for Stenoparib DRP® Companion Diagnostic, Further Strengthening Stenoparib Development

TARPON SPRINGS, Fla., September 15, 2026 – Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a differentiated, dual PARP and WNT pathway inhibitor—today announced that the Japan Patent Office (JPO) has granted a key patent covering Allarity’s proprietary stenoparib-specific Drug Response Predictor (DRP®) companion diagnostic. The newly granted patent, Japanese Patent No. 7917283, p

14d agoYahoo! Finance Canada

Allarity Therapeutics files for $100 million SPAC offering

18d agoInvesting.com

Allarity Therapeutics reports Q2 results, cash position

1mo agoInvesting.com

Allarity Therapeutics Reports Second Quarter 2026 Results and Completion of the Phase 3-Ready Stenoparib Manufacturing Campaign

- Completed quarter with $26.9 million in cash and restricted cash - Key U.S. patent was awarded, protecting exclusivity of stenoparib when used with the stenoparib-specific DRP® companion diagnostic into 2042 - AACR 2026 data linked higher stenoparib DRP® scores with enhanced overall survival in advanced ovarian cancer, further supporting DRP®-guided patient selection - Obtained CLIA certification for its in-house laboratory, enabling full control of DRP® testing to accelerate and support U.S.

1mo agoYahoo Finance

Also Discussed

Investors talking about ALLR also mention

#	Name	Attention
1	Femto Technologies Inc.BCAN	0%0
2	SOBR Safe, Inc.SOBR	0%0
3	Cheetah Net Supply Chain Service Inc.CTNT	0.02%-0.01
4	TransCode Therapeutics, Inc.RNAZ	0%+0
5	Freight Technologies, Inc.FRGT	0%-0.01
6	U Power Limited Class A Ordinary SharesUCAR	0%0
7	Crown Electrokinetics Corp.CRKN	0%0
8	MicroAlgo Inc.MLGO	0%new
9	CGBS - Crown LNG Holdings Limited	——
10	TCBP - TC Biopharm (Holdings) Plc	——

Allarity Therapeutics Inc.

Healthcare
Biotechnology

Allarity Therapeutics Inc. is a clinical-stage precision medicine biopharmaceutical company focused on developing personalized cancer treatments. Its current work centers on stenoparib, an investigational therapy being studied for advanced recurrent ovarian cancer, alongside its proprietary Drug Response Predictor technology, which is designed to help identify patients most likely to benefit from specific oncology drugs. The company also supports a limited portfolio of additional cancer-focused programs and companion diagnostics intended to improve treatment selection and clinical decision-making. Allarity Therapeutics operates primarily in the oncology and drug development segments, with activities in the United States and Denmark. As a specialist in biomarker-guided cancer care, the company occupies a niche role in the broader pharmaceutical market by combining therapeutic development with diagnostic tools to support more targeted treatment approaches.

Website

Location

123 E. Tarpon Ave.

Tarpon Springs, FL, 34689

United States

Social

What share of all stock conversation is about ALLR?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% -0.01	0% +0	0% +0	0% -0.02

Sep 15

Allarity Therapeutics, Inc. (ALLR) granted Japanese patent for Stenoparib DRP companion diagnostic, strengthening its development.
The patent establishes an IP moat for ALLR in the multi-billion dollar Asian oncology sector through 2039, materially de-risking ongoing Phase 2 clinical trials.
The development of Stenoparib DRP companion diagnostic has significant potential, according to some market participants.

Generated by AI

Sentiment

Of the messages about ALLR that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100% +12.24	72.29% +52.06	61.93% -28.47	75.2% -11.86
Bearish	0% -12.24	27.71% -52.06	38.07% +28.47	24.8% +11.86

Bullish· May 27

The author believes $ALLR has the potential for a big break out, citing a strong price increase.
The stock is expected to move higher, with a target price of $1.87 and potentially even $2.30.
The author is confident in the stock's ability to make significant gains, comparing it to other successful stocks that have experienced rapid price increases.

Bearish· Feb 3

The company's recent offering of shares may be part of a scam, as it was launched during the FDA shutdown when no news was expected.
The stock's price compression and fading downside momentum suggest a sharp move, which could be downward.
The company's leadership and PR efforts are being criticized, with some calling the CEO a "scam artist" and the stock a "trash" that will inevitably sink.

Generated by AI

Topics

Of the messages about ALLR that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	100%	89.2%	74.02%
Technical Analysis	0%	0%	10.8%	21.86%
Controversies	0%	0%	0%	1.03%
Earnings	0%	0%	0%	0.75%
Macro	0%	0%	0%	0.83%
Analysts	0%	0%	0%	1.5%

Announcements· Sep 22

Allarity Therapeutics, Inc. ($ALLR) presents new Phase 2 clinical data for Stenoparib/2X-121, showing a landmark median overall survival (mOS) exceeding 25 months in platinum-resistant ovarian cancer.
The company has secured a $2.5 million private placement at $1.60 per share, with an institution, in addition to its Fast Track designation and multiple upcoming conferences.
The data presented at the American Association for Cancer Research (AACR) demonstrate clinical benefit in both BRCA-wt and BRCA-mut patients, indicating a potential for Stenoparib to reach a larger patient population.

Technical Analysis· Aug 27

$ALLR has formed a cup and handle pattern, potentially indicating a continuation of the upward trend.
The stock has reached the target of a double bottom pattern on the 15-minute chart and is nearing the target of a falling wedge pattern.
The stock is expected to break out if it opens near $0.50, targeting $0.70 and $0.90, following FDA approval for a cancer treatment.

Generated by AI

Community

Of the messages about ALLR, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	54.29%	76.87%	85.99%	91.71%
Newcomers	45.71%	23.13%	14.01%	8.29%

Regulars· Sep 11

Allarity Therapeutics, Inc. (ALLR) is planning to raise $100M+ through a proposed IPO, with the stage set for stenoparib news to be announced.
The company's SPAC, Allarity Acquisition Corp. (ALLNU), is expected to have a base offering size of $100M, with the sponsor owning approximately 25% of the company.
Stenoparib's patent protection could potentially be extended, and the company could apply the same strategy to other drugs, providing a 25% economic benefit.

Newcomers· Sep 24

Newcomers to Allarity Therapeutics are focusing on the company's clinical trial results, with some highlighting the stock's potential for growth due to its promising oncology treatments.
The recent funding of $250M is seen as a positive development for Allarity Therapeutics, potentially positioning it ahead of competitors in the aerospace and defense sectors.
The stock's recent performance is being attributed to Allarity's focus on expanding its therapeutic pipeline, which could yield positive results and reflect broader market trends.

Generated by AI

Allarity Therapeutics

Social

Sep 15

Bullish· May 27

Bearish· Feb 3

Announcements· Sep 22

Technical Analysis· Aug 27

Regulars· Sep 11

Newcomers· Sep 24

Allarity expands lab capabilities to support drug research

Allarity Therapeutics Expands Laboratory Capabilities to Include Proteomics and Cell Line Research

Allarity Therapeutics Granted Japanese Patent for Stenoparib DRP® Companion Diagnostic, Further Strengthening Stenoparib Development

Allarity Therapeutics files for $100 million SPAC offering

Allarity Therapeutics reports Q2 results, cash position

Allarity Therapeutics Reports Second Quarter 2026 Results and Completion of the Phase 3-Ready Stenoparib Manufacturing Campaign

Also Discussed

Allarity Therapeutics Inc.

Company Information

Location

Allarity expands lab capabilities to support drug research

Allarity Therapeutics Expands Laboratory Capabilities to Include Proteomics and Cell Line Research

Allarity Therapeutics Granted Japanese Patent for Stenoparib DRP® Companion Diagnostic, Further Strengthening Stenoparib Development

Allarity Therapeutics files for $100 million SPAC offering

Allarity Therapeutics reports Q2 results, cash position

Allarity Therapeutics Reports Second Quarter 2026 Results and Completion of the Phase 3-Ready Stenoparib Manufacturing Campaign

Also Discussed

Social

Sep 15

Bullish· May 27

Bearish· Feb 3

Announcements· Sep 22

Technical Analysis· Aug 27

Regulars· Sep 11

Newcomers· Sep 24